Ultralife (ULBI) Common Equity (2010 - 2026)

Ultralife's Common Equity history runs 17 years deep, the most recent figure standing at $129.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 5.11% year-over-year to $129.6 million; the TTM figure through Mar 2026 stood at $129.6 million (down 5.11% YoY), while the FY2025 annual figure was $130.1 million, down 3.02% from the prior year.
• Common Equity was $129.6 million for Q1 2026 at Ultralife, roughly flat from $130.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $138.6 million in Q2 2025 to a low of $115.2 million in Q3 2022.
• Historically, Common Equity has averaged $126.6 million across 5 years, with a median of $128.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity rose 11.42% in 2024, then fell 5.11% in 2026.
• A 5-year view of Common Equity shows it stood at $116.3 million in 2022, then advanced by 7.87% to $125.4 million in 2023, then climbed by 6.98% to $134.2 million in 2024, then slipped by 3.02% to $130.1 million in 2025, then declined by 0.39% to $129.6 million in 2026.
• The last three Common Equity figures came in at $129.6 million (Q1 2026), $130.1 million (Q4 2025), and $137.4 million (Q3 2025), per Business Quant data.